NextCure To Present Phase 1b Data On NC410 And Pembrolizumab Combination at ASCO 2024 June 1, 2024
Portfolio Pulse from Benzinga Newsdesk
NextCure, Inc. (NASDAQ:NXTC) will present Phase 1b data on the combination of NC410 and pembrolizumab at the ASCO 2024 Annual Meeting. The trial showed promising results in MSS/MSI-L CRC and ovarian cancer patients, with notable disease control rates.

May 30, 2024 | 8:43 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
NextCure will present positive Phase 1b data on NC410 and pembrolizumab combination at ASCO 2024, showing promising results in MSS/MSI-L CRC and ovarian cancer patients.
The presentation of positive clinical data at a major conference like ASCO is likely to boost investor confidence and potentially drive the stock price up in the short term. The promising results in hard-to-treat cancers add to the significance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100